Literature DB >> 30697362

The effect of lunasin from Indonesian soybean extract on histopatologic examination and cox-2 expression in dextran sodium sulfate-induced mice colon.

Kusmardi Kusmardi1, Nessa Nessa2, Ari Estuningtyas3, Aryo Tedjo4.   

Abstract

Inflammatory bowel disease (IBD) is a condition describing chronic gastrointestinal inflammation. Chronic inflammation in colon can develop into colon cancer. Lunasin has been known to inhibit inflammatory reactions induced by lipopolysaccharide in vitro. The effect of lunasin to inhibit inflammation in vivo is not widely known. In this study, we analyzed the effect of lunasin from soybean to decrease the risk of inflammation by analyzing histopathologic feature and the expression of COX-2. 30 mice are divided into 6 groups. Normal group was not induced by dextran sodium sulfate (DSS). The other groups were induced by 2% DSS through drinking water for 9 days. After 9 days, negative control group did not receive any treatment. The other groups received treatment given lunasin dose 20 mg/kg body weight (BW) and 40 mg/kg BW, commercial lunasin and positive control given aspirin. Treatment was performed for 5 weeks. Inflammatory colon histopathologic examination and immunohistochemical score of COX-2 proteins were analyzed using statistical tests. Lunasin dose 20 mg/kg BW and 40 mg/kg BW were able to significantly reduce inflammation (P<0.05) performed by histopathologic feature with an average score of 2.52 and 2.16 COX-2 expression decreased significantly (P<0.05) with an average score of 43.674 and 33.349. Lunasin dose 20 mg/kg BW and 40 mg/kg BW were able to inhibit inflammation and decrease the expression of COX-2 in colon induced by DSS.

Entities:  

Keywords:  COX-2; Inflammation; histopathology; lunasin

Year:  2018        PMID: 30697362      PMCID: PMC6334218     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  24 in total

Review 1.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Authors:  Peter-Laszlo Lakatos; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

Review 2.  Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.

Authors:  Imke Atreya; Markus F Neurath
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

Review 3.  Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.

Authors:  Pia Munkholm; Edward V Loftus; Anke Reinacher-Schick; Asher Kornbluth; Ulrich Mittmann; Burak Esendal
Journal:  Digestion       Date:  2006-01-10       Impact factor: 3.216

4.  The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in southeastern Norway.

Authors:  Geir Aamodt; Geir Bukholm; Jørgen Jahnsen; Bjørn Moum; Morten H Vatn
Journal:  Am J Epidemiol       Date:  2008-09-18       Impact factor: 4.897

5.  The Role of Inflammation in the Pathogenesis of Colorectal Cancer.

Authors:  Beth B McConnell; Vincent W Yang
Journal:  Curr Colorectal Cancer Rep       Date:  2009-04-01

6.  Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice.

Authors:  Rikako Suzuki; Hiroyuki Kohno; Shigeyuki Sugie; Hitoshi Nakagama; Takuji Tanaka
Journal:  Carcinogenesis       Date:  2005-08-04       Impact factor: 4.944

7.  Family history as a risk factor for colorectal cancer in inflammatory bowel disease.

Authors:  J Askling; P W Dickman; P Karlén; O Broström; A Lapidus; R Löfberg; A Ekbom
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

8.  Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.

Authors:  E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

Review 9.  Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.

Authors:  P Munkholm
Journal:  Aliment Pharmacol Ther       Date:  2003-09       Impact factor: 8.171

10.  Lunasin and lunasin-like peptides inhibit inflammation through suppression of NF-kappaB pathway in the macrophage.

Authors:  Elvira Gonzalez de Mejia; Vermont P Dia
Journal:  Peptides       Date:  2009-08-12       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.